室性心动过速(VT),和它的发生,仍然是心脏猝死的主要原因之一,因此,对于结构性心脏[KahleA-K,JungenC,AlkenF-A,ScherschelK,WillemsS,PürerfellnerH等人。缺血性心肌病患者室性心动过速的管理:当代医疗设备。Europace2022;24:538-51]。导管消融术已成为复发性室性心动过速患者安全有效的治疗选择[CroninEM,BogunFM,莫里·P,PeichlP,陈M,NamboodiriN等人。2019年HRS/EHRA/APHRS/LAHRS关于室性心律失常导管消融的专家共识声明。心律2020;17:e2-154]。以前和目前的指南为VT消融术的指征以及潜在疾病的风险评估和评估提供指导。然而,没有提供关于程序策略的统一建议,消融时间,和中心设置。因此,这些细节似乎有很大的不同,和最近的数据是稀疏的。这项以医生为基础的欧洲心律协会调查旨在提供不仅对基础设施设置,而且对程序细节的见解。应用技术,消融策略,和程序端点。因此,这些发现可能提供真实的室性心动过速管理方案,并可能为其他中心提供指导.
Ventricular tachycardia (VT), and its occurrence, is still one of the main reasons for sudden cardiac death and, therefore, for increased mortality and morbidity foremost in patients with structural heart [Kahle A-K, Jungen C, Alken F-A, Scherschel K, Willems S, Pürerfellner H et al. Management of ventricular tachycardia in patients with ischaemic cardiomyopathy: contemporary armamentarium. Europace 2022;24:538-51]. Catheter ablation has become a safe and effective treatment option in patients with recurrent VT [Cronin EM, Bogun FM, Maury P, Peichl P, Chen M, Namboodiri N et al. 2019 HRS/EHRA/APHRS/LAHRS expert
consensus statement on catheter ablation of ventricular arrhythmias. Heart Rhythm 2020;17:e2-154]. Previous and current
guidelines provide guidance on indication for VT ablation and risk assessment and evaluation of underlying disease. However, no uniform recommendation is provided regarding procedural strategies, timing of ablation, and centre setting. Therefore, these specifics seem to differ largely, and recent data are sparse. This physician-based European Heart Rhythm Association survey aims to deliver insights on not only infrastructural settings but also procedural specifics, applied technologies, ablation strategies, and procedural endpoints. Therefore, these findings might deliver a real-world scenario of VT management and potentially are of guidance for other centres.